Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPATE vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Major depressive disorder,Generalized anxiety disorder,Panic disorder,Social anxiety disorder,Obsessive-compulsive disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Hypertension
50 mg orally once daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal half-life of 12-15 hours (range 10-18h) in adults; prolonged in renal impairment (up to 30h in severe cases).
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hepatic primarily via CYP2C19, CYP2D6, CYP3A4, and CYP2C9; active metabolite desmethylsertraline.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal excretion of unchanged drug (60-80%); biliary/fecal elimination accounts for 15-20%.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
95-98% bound, primarily to albumin and alpha-1-acid glycoprotein.
~90%, primarily to albumin
0.5-0.7 L/kg (suggests moderate tissue penetration; primarily extracellular distribution).
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 70-80% (first-pass metabolism 20-30%; food reduces absorption by 10-15%).
Oral: 50–60% (extensive first-pass metabolism)
No dosage adjustment required for GFR ≥30 m L/min; GFR <30 m L/min: not recommended.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 25 mg once daily; Child-Pugh C: not recommended.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not approved for pediatric use.
Not recommended for pediatric use; safety in children under 12 years not established.
No dosage adjustment required; monitor renal function.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
None
Suicidality risk in pediatric/young adult patients,Serotonin syndrome risk with concomitant serotonergic drugs,Bleeding risk with anticoagulants/antiplatelets,Activation of mania/hypomania,Seizure risk in patients with epilepsy,Angle-closure glaucoma risk,Hyponatremia risk in elderly/dehydrated patients,Discontinuation syndrome with abrupt cessation
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Concurrent MAOIs (including linezolid and methylene blue),Concurrent pimozide,Known hypersensitivity to sertraline
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Grapefruit and grapefruit juice may increase sertraline levels; avoid consumption.,Alcohol: Avoid or limit intake to prevent worsening of side effects and reduced drug efficacy.,St. John's Wort: Concomitant use increases risk of serotonin syndrome; avoid.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
SERPATE is contraindicated in pregnancy. First trimester exposure carries risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. For all trimesters, increased risk of spontaneous abortion and stillbirth has been reported.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
SERPATE is excreted into human breast milk. Milk-to-plasma ratio is approximately 2:1. Breastfeeding is not recommended during therapy due to potential for severe adverse reactions in the nursing infant. Advise women to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Due to significant pharmacokinetic changes in pregnancy, including increased clearance (by 50%) and expanded volume of distribution, the dose of SERPATE should be increased by 30% during the second and third trimesters. Monitor therapeutic drug levels to maintain trough concentrations within the target range. Postpartum, reduce to prepregnancy dose within 48 hours to avoid toxicity.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
SERPATE is a brand name for sertraline, a selective serotonin reuptake inhibitor (SSRI). Initiate at 25-50 mg daily, titrate up to 200 mg maximum. Monitor for serotonin syndrome, especially with other serotonergic drugs. Abrupt discontinuation may cause withdrawal symptoms; taper gradually. Use with caution in bipolar disorder due to risk of manic switching. Adjusted dosing may be needed in hepatic impairment; no adjustment for renal impairment. May increase risk of bleeding, especially with NSAIDs or anticoagulants. Monitor for hyponatremia in elderly or volume-depleted patients.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take sertraline exactly as prescribed, usually once daily with or without food.,It may take 2-4 weeks to feel full benefit; do not stop abruptly without consulting your doctor.,Common side effects include nausea, diarrhea, dry mouth, dizziness, and trouble sleeping; these often improve over time.,Contact your doctor immediately if you experience signs of serotonin syndrome (e.g., agitation, hallucinations, fever, fast heart rate, muscle stiffness, twitching, coordination problems) or bleeding (e.g., unusual bruising, nosebleeds).,Avoid alcohol, as it can worsen side effects and reduce drug effectiveness.,Inform all healthcare providers that you are taking sertraline, especially before surgery or any procedure.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks and benefits with your doctor.,Do not take with MAO inhibitors (e.g., linezolid, methylene blue) or within 14 days of stopping them.,Store at room temperature away from moisture and heat.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPATE vs ALDORIL 15, answered by our medical review team.
SERPATE is a Antihypertensive that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPATE and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPATE is: 50 mg orally once daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPATE and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPATE is classified as Category C. SERPATE is contraindicated in pregnancy. First trimester exposure carries risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second . ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.